Form 4: Centessa Pharmaceuticals General Counsel Iqbal Hussain Reports Share Sales

Iqbal Hussain, General Counsel of Centessa Pharmaceuticals, reports the sale of ordinary shares acquired through option exercises, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• Iqbal Hussain, the General Counsel of Centessa Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On April 25, 2025, Hussain exercised options to acquire 3,609 ordinary shares at a price of $5.84 per share and then sold the same amount at a weighted average price of $14.0001.
• On April 28, 2025, Hussain exercised options to acquire 2,080 ordinary shares at a price of $5.84 per share and then sold the same amount at a weighted average price of $14.0056.
• These sales were executed under a Rule 10b5-1 trading plan adopted on September 14, 2024.
• Following these transactions, Hussain directly owns 105,386 ordinary shares and indirectly owns 5,500 ordinary shares through a spouse.
• Hussain also holds options to purchase 303,870 ordinary shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions. The use of a 10b5-1 plan suggests no negative implications.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Comparing the insider trading activity of Centessa Pharmaceuticals to similar biotech companies requires analyzing the frequency and size of transactions, as well as the context in which they occur.
• For example, companies like Amgen or Gilead Sciences also have executives who regularly trade shares, but the scale and reasons for these trades can vary significantly.
• A key benchmark is whether the trades are conducted under pre-arranged trading plans like Rule 10b5-1, which is a common practice to avoid accusations of insider trading based on non-public information.

Stakeholder Impact

• The reported transactions may have a minor impact on shareholders, as insider selling can sometimes be perceived negatively, although the use of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Form 4, Centessa Pharmaceuticals, Insider Trading, Share Options, Beneficial Ownership, Rule 10b5-1, CNTA, Iqbal Hussain, General Counsel, Share Sales